SHARPE
Reported results
- First half net sales increased 6% to $10.89 million from $10.30 million in the prior-year period
- First half gross profit increased 14% to $5.98 million with gross margin expanded to 55% from 51%
- First half operating income increased 41% to $1.28 million from $905,000
- First half medical market sales increased 289% to $7.05 million, led by balloon coating and specialty stent-coating systems
- Cash, cash equivalents and marketable securities totaled $17.7 million at August 31, 2026, with no outstanding debt
- Backlog of $9.51 million at August 31, 2026, increased 23% from $7.73 million at end of first quarter; subsequent orders totaling $7.19 million expected to ship in fiscal 2028
Guidance
- Company reiterates expectation of flat to modest revenue growth for full fiscal year 2027, reflecting timing of several large orders
Notes
Release compares fiscal 2027 results to fiscal 2026 prior-year periods. All figures are GAAP. Second quarter net sales increased 1% to $5.23 million; second quarter net income was $366,000 or $0.02 per diluted share. First half net income increased 22% to $1.11 million.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-14 (8-K, Item 2.02). Read the original filing on sec.gov.